Ayala Pharmaceuticals Inc (ADXS)

[mpreorder]

Nothing new to us, we've seen this all before. It's just a re-evaluation of the data. What I think is new is "The probability of this survival improvement being detected by chance versus a true treatment effect was calculated to be 0.02. A compelling and ongoing complete response of 18.5 months was observed and the longest ongoing survival is 40.6 months."
So...it works - already knew that.
So....it's durable in a subset of patients - strongly suspected that. Now we need to determine which patients which will require a larger patient population to determine.
I guess we may see a small pop today, followed by the usual pullback later this week. Please don't flame me for this....it's typical for Adxs.